Stock Events

Stock Events

XOMA 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q1 2026
Next
0.11
0.12
0.14
0.15
Expected EPS
0.15467048800000002
Actual EPS
N/A

Financials

59.64%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
45.54MRevenue
27.16MNet Income

Analyst Ratings

33.77Average Price Target
The highest estimate is 37.94.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow X0M1.STU. It's not an investment recommendation.
Microsoft
10
MSFT
Tesla
9
TSLA
Apple
8
AAPL
Realty Income
8
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals competes in the biotechnology industry focusing on developing and commercializing medicines for serious medical conditions, similar to XOMA's focus on antibody-based therapeutics.
AMGEN
AMGN
Mkt Cap196.12B
Amgen is a biopharmaceutical company that discovers, develops, manufactures, and delivers innovative human therapeutics, competing directly with XOMA in the biotech sector.
Biogen
BIIB
Mkt Cap29.4B
Biogen competes with XOMA in the biotechnology field, focusing on developing therapies for neurological and neurodegenerative diseases.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to XOMA, making them direct competitors.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is involved in creating new possibilities in medicine to cure diseases and improve people's lives, competing with XOMA in the biotech innovation space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with XOMA in the development of novel therapeutics.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, making it a competitor in the biopharmaceutical space alongside XOMA.
Nektar Therapeutics
NKTR
Mkt Cap2.38B
Nektar Therapeutics is involved in developing new treatment options in various therapeutic areas, competing with XOMA in the innovation of biologic drugs.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical focuses on developing and commercializing innovative biopharmaceuticals for rare diseases, competing with XOMA in targeting niche markets with specialized treatments.

About

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Show more...
CEO
Mr. Owen P. Hughes Jr.
Employees
14
Country
Germany
ISIN
US98419J2069

Listings

STU
DE
X0M1.STU
MU
DE
X0M1.MU
BOATS
BOATS
XOMAO.BOATS
LSE
GB
0M26.LSE

0 Comments

Share your thoughts

FAQ

What is XOMA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange XOMA stocks are traded under the ticker X0M1.STU.
When is the next XOMA earnings date?▼
XOMA is going to release the next earnings report on July 30, 2026.
What were XOMA earnings last quarter?▼
X0M1.STU earnings for the last quarter are 0.14 EUR per share, whereas the estimation was 0.11 EUR resulting in a +30.54% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is XOMA revenue for the last year?▼
XOMA revenue for the last year amounts to 45.54M EUR.
What is XOMA net income for the last year?▼
X0M1.STU net income for the last year is 27.16M EUR.
How many employees does XOMA have?▼
As of July 14, 2026, the company has 14 employees.
In which sector is XOMA located?▼
XOMA operates in the Health & Wellness sector.
When did XOMA complete a stock split?▼
XOMA has not had any recent stock splits.
Where is XOMA headquartered?▼
XOMA is headquartered in EmeryVille, Germany.